Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-1-syntrophin is a cytoplasmic peripheral membrane adapter protein encoded by the human SNTG1 gene on chromosome 8. It contains two pleckstrin homology (PH) domains, a PDZ domain, and a C-terminal domain that can bind dystrophin. SNTG1 is expressed predominantly in the brain and is important for organizing the subcellular localization of various proteins, often by linking receptors to cellular structural frameworks such as the actin cytoskeleton and dystrophin glycoprotein complex. Additionally, it plays a role in regulating the positioning and inactivation of molecules like diacylglycerol kinase-zeta following receptor activation and is involved in trafficking gamma-enolase to the plasma membrane to enhance neurotrophic activity. Genetic variants and abnormalities in SNTG1 have been associated with several neurological and autoimmune diseases, but SNTG1 is not presently considered a direct therapeutic target such as a receptor, enzyme, or transporter[1][2][3][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-1-syntrophin (SNTG1).